Minulet (Ethinylestradiol, Gestodene)

Ethinylestradiol (an estrogen) and gestodene (a progestogen) suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating an environment that is unfavorable for fertilisation and implantation.

The dosing regimen for Minulet is determined by the prescribing clinician. Typically, the product is taken once daily for a defined cycle, but the exact schedule, including any hormone‑free interval, should follow the prescriber’s instructions and the product label.

Minulet is contraindicated during pregnancy; it should be stopped immediately if pregnancy is confirmed. While limited data exist for breastfeeding, most guidelines advise caution and recommend discussing alternative contraceptive options with a healthcare professional.

To order Minulet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Minulet contains ethinylestradiol and gestodene, a low‑dose progestogen that offers a favorable bleeding profile and reduced androgenic activity compared with some older formulations. Its efficacy in preventing pregnancy is comparable to other approved combined oral contraceptives, while the side‑effect spectrum may differ slightly based on individual hormone sensitivities.

Store Minulet at ambient temperature, preferably below 25 °C, in its original blister pack to protect from moisture and light. Keep the tablets out of reach of children and do not use the product after the expiry date printed on the packaging.

Minulet is taken orally, usually once each day at the same time, with or without food. Patients should follow the prescribing information regarding the start day of the cycle and any hormone‑free interval, and should not miss doses to maintain contraceptive effectiveness.

The most serious risks include venous thromboembolism, arterial thrombosis, severe hypertension, and rare allergic reactions such as anaphylaxis. Women who smoke, have a history of clotting disorders, or possess cardiovascular risk factors should be monitored closely and advised to seek immediate medical attention if symptoms arise.

Minulet is contraindicated in women who are pregnant, have a known or suspected estrogen‑dependent tumor, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.